In brief:
- Buffet and his team added pharmaceutical stocks AbbVie, Bristol Myers Squibb, Merck, and Pfizer to its stock portfolio in the third quarter.
- Sold 3% of Berkshire Hathaway’s Apple shares
- Reduced his exposure to the financial sector by selling 95% of the JPMorgan Chase investment, Wells Fargo (-46%), MTB (-35%) ,and PNC Financial Services (-64%).
Warren Buffett’s Berkshire Hathaway made some major changes to its equity portfolio in the third quarter, including building new sizeable stakes in a few pharmaceutical stocks. He also reduced his long-term stake in JPMorgan Chase investment by 95% and sold some of his Apple position.
Berkshire Hathaway bought 21.3 million shares of Abbvie (ABBV), 22.4 million shares of Merck, 3.7 million shares of Pfizer (PFE) and 29.97 million shares in Bristol-Myers Squibb (BMY) in the third quarter, according to a new 13F filing. Berkshire also picked up 2.4 million shares of T-Mobile (TMUS) last quarter.
Berkshire cut also its Barrick Gold position by more than 40%, despite only investing in the gold miner for the first time in the second quarter. He also closed the Costco (COST) position of 4,333,363 shares.
Dividend Aristocrats
Berkshire Hathaway has only four dividend aristocrats in its portfolio, which are:
Holdings are as of September 30, 2020, as reported in Berkshire Hathaway’s 13F filing on November 16, 2020.
See also our Buffett portfolio tracker for the latest market values.
